Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.62 |
| ▸ | DRD3 | P35462 | 15/20 | 0.62 |
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323800 | 0.89 | ADRB1 (0.55) | DRD2DRD3DRD4ADRB1RAB9A | |
| SCHEMBL17996843 | 0.83 | ALDH1A1 (0.50) | DRD2DRD3DRD4ADRB1DHODH | |
| SCHEMBL29282473 | 0.83 | DRD2 (0.67) | DRD2DRD3DRD4ADRB1DHODH | |
| SCHEMBL1194044 | 0.79 | DRD2 (0.61) | DRD2DRD3DRD4OPRK1DRD5 | |
| SCHEMBL27921833 | 0.79 | DRD2 (0.61) | DRD2DRD3DRD4ADRB1OPRK1 | |
| SCHEMBL3398184 | 0.78 | DRD2 (0.70) | DRD2DRD3DRD4ADRB1DHODH | |
| SCHEMBL8452211 | 0.77 | DRD2 (0.69) | DRD2DRD3DRD4ADRB1DHODH | |
| SCHEMBL18950672 | 0.77 | DRD2 (0.68) | DRD2DRD3DRD4ADRB1DHODH | |
| SCHEMBL8318459 | 0.77 | DRD2 (0.68) | DRD2DRD3DRD4ADRB1DHODH | |
| SCHEMBL13457329 | 0.77 | DRD2 (0.68) | DRD2DRD3DRD4ADRB1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | DRD2 187/4885DRD3 160/4885DRD4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.